Tuojie Biotech (Shanghai) Co. Ltd. has described apelin receptor (APLNR) agonists reported to be useful for the treatment of neurological disorders, cardiovascular disorders, obesity, diabetes, chronic kidney diseases and diabetic nephropathy.
Tuojie Biotech (Shanghai) Co. Ltd. has prepared oxygen-containing fused tricyclic derivatives acting as CDK2/cyclin E1 and/or CDK4/cyclin D1 inhibitors. As such, they are reported to be potentially useful for the treatment of cancer, infections, autoimmune disease and inflammatory disorders.
Tuojie Biotech (Shanghai) Co. Ltd. has divulged cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of autoimmune diseases, cancer, infections and inflammatory disorders.
Researchers at Tuojie Biotech (Shanghai) Co. Ltd. have developed substituted 1,4-dihydro-1,6-naphthyridine amides characterized as mineralocorticoid receptor (MR) antagonists and reported to be useful for the treatment of hypertension, aldosteronism and heart failure.
Tuojie Biotech (Shanghai) Co. Ltd. has described lysophosphatidic acid receptor 1 (LPAR1) antagonists reported to be useful for the treatment of metabolic diseases, cancer, liver diseases, respiratory, renal, neurological, cardiovascular and eye disorders, among others.
Tuojie Biotech (Shanghai) Co. Ltd. has divulged cyclin-dependent kinase 2 (CDK2)/cyclin E inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Tuojie Biotech (Shanghai) Co. Ltd. has identified mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, inflammation and autoimmune diseases.
Tuojie Biotech (Shanghai) Co. Ltd. has disclosed boric acid derivatives acting as β-lactamase (bacterial) inhibitors reported to be useful for the treatment of bacterial infections.
